<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Twenty-two patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> were treated with combined recombinant human erythropoietin and recombinant human interleukin 3 (rHuIL-3) </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 22 patients were evaluable for toxicity and 21/22 for response </plain></SENT>
<SENT sid="2" pm="."><plain>Thirteen patients (62%) required rHuIL-3 dose reduction because of toxicity </plain></SENT>
<SENT sid="3" pm="."><plain>Nineteen experienced a 50% or greater rise in neutrophil count </plain></SENT>
<SENT sid="4" pm="."><plain>Of seven patients with initial platelet counts of &gt; 100,000, three experienced increases of &gt; 15,000/ml while an equal number had a comparable decline </plain></SENT>
<SENT sid="5" pm="."><plain>Five patients (21%) experienced a significant rise in reticulocyte count, and two transfusion-dependent patients experienced a significant decrease in transfusions </plain></SENT>
<SENT sid="6" pm="."><plain>Erythroid burst-forming units were increased by &gt; or = 50% in nine of 11 patients after combined therapy </plain></SENT>
<SENT sid="7" pm="."><plain>Similar changes were seen in multipotential colony-forming units </plain></SENT>
<SENT sid="8" pm="."><plain>Clinical responses were comparable to results obtained with epo alone while toxicities due to IL-3 were significant </plain></SENT>
</text></document>